Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter,

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

How to Treat MDS without Stem Cell Transplantation

Figure 1 Chimeric antigen receptor (CAR) structures

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

Vaccination of Children following Allogeneic Stem Cell Transplantation

Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care? Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Allogeneic Stem Cell Transplantation in Myelofibrosis

Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients Bernard Lawrence Marini, Sung Won Choi, Craig Alan Byersdorfer, Simon.

Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells Saad S. Kenderian, Marco.

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Transplantation of Umbilical Cord Blood–Derived Cells for Novel Indications in Regenerative Therapy or Immune Modulation: A Scoping Review of Clinical.

Sabina Kersting, Leo F. Verdonck

Access to Hematopoietic Cell Transplantation in the United States

Caroline F. Morrison, Donna M

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia Saad S. Kenderian, MD, Marco Ruella, MD,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

The Other Face of Chimeric Antigen Receptors

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Visualizing the Immune Synapse

Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies Stefan O. Ciurea, Richard.

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

B Cells and Transplantation: An Educational Resource

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model Saad S. Kenderian,

Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Chimeric antigen receptor T-cell therapy for solid tumors

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives Minakshi Raj, Sung Won Choi,

Blood and Marrow Transplant Handbook

Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Fig. 1 Engineered T cells: design of TCR versus CAR T cells.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Presentation transcript:

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter, Saar Gill Biology of Blood and Marrow Transplantation Volume 23, Issue 2, Pages 235-246 (February 2017) DOI: 10.1016/j.bbmt.2016.09.002 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Composition of a CAR. A CAR is composed of an extracellular single-chain variable fragment, linked to a transmembrane domain (CD8 or CD28) through a hinge (CD8 or IgG4), 1 or more intracellular costimulatory molecules (41BB, CD28, CD27, ICOS, and/or OX40), and a CD3z signaling molecule. Biology of Blood and Marrow Transplantation 2017 23, 235-246DOI: (10.1016/j.bbmt.2016.09.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Schematic showing how CART cell therapy can be incorporated in hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2017 23, 235-246DOI: (10.1016/j.bbmt.2016.09.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Schematic showing how myeloid CART cell therapy can be used in a novel conditioning regimen as a way to induce antileukemic activity and myeloablation. Biology of Blood and Marrow Transplantation 2017 23, 235-246DOI: (10.1016/j.bbmt.2016.09.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions